Timing of Surgery After Neoadjuvant Chemotherapy for Advanced Ovarian Cancer

Ovarian cancer is among the top five primary causes of cancer-related mortality in women. Most ovarian malignant tumours originate from epithelial cells The majority of patients typically have advanced-stage tumours at diagnosis. When complete surgery with no macroscopic visible disease is not feasible due to both the spread of the disease and the patient's general condition, neoadjuvant chemotherapy (NACT) of 3 cycles followed by interval cytoreductive surgery (ICS) or final cytoreductive surgery (FCS) after 6 cycles of NACT followed or not by adjuvant chemotherapy can be offered, with simila

Trial Details

NCT ID
NCT06404671
Phase
NA
Sponsor
Alexandria University
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Delayed interval cytoreductive surgery (DICS)
  • Early interval cytoreductive surgery (EICS)
Locations (sample)
  • Alexandria, Egypt|31.20176,29.91582

Key Eligibility Criteria

  • Female Patients aged 18 to 75 years.
  • International Federation of Gynecology and Obstetrics (FIGO) stage IIIB-IV unsuitable for UCS.
  • Histologically confirmed high-grade serous (HGS) ovarian, fallopian tube, or primary peritoneal carcinoma.
  • ECOG performance status: 0 or 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →